HOME >> BIOLOGY >> NEWS
Braunschweig Prize 2003 for Molecular Cancer Therapy

Ten years ago the medic began working with the compound Imatinib that works against chronic myeloid leukemia (CML) and is commercially known as Glivec. Glivec blocks a protein that triggers the uncontrolled reproduction of white blood cells. "The name Brian Druker has become synonymous with a breakthrough in cancer therapy," said Braunschweig's mayor and chairman of the jury, Dr. Gert Hoffmann on the 8th of July after the vote of the council. Every year approximately 1700 people in Germany fall ill with CML. Some of the first patients to be treated with Glivec came from Germany.

Druker received his M.D. in 1981 from the University of California in San Diego. At Harvard Medical School he specialized in cancer research. Since 1993, Druker leads leukemia research at the Oregon Health & Science University Cancer Institute in Portland (USA). He is Investigator of the Howard Hughes Medical Institute and JELDWEN Chair of Leukemia Research. On the 27th of October he will accept the Braunschweig prize at the congress "Life in Tomorrow's World."

The American cancer researcher Prof. Dr. Brian Druker will be recognised for his research into molecular cancer ther-apy with the 50,000 Euro Braunschweig Prize, the highest research prize from a German city.

The 48-year-old medic is regarded as the pathfinder of the first tailor-made pill for the treatment of cancer. Ten years ago, in collaboration with the pharmaceutical company No-vartis, he identified the compound Imatinib, which in the meantime has become commercially available as Glivec. In contrast to chemotherapy that attacks both healthy and diseased cells, Imatinib targets a single protein that trig-gers the uncontrolled growth of white blood cells in chronic myeloid leukemia (CML). Every year approximately 1700 people in Germany fall ill with this blood cancer.

A recent study involving 1006 patients, comparing Glivec to standard therapy for CML, led by Druker, had to be stopped early because
'"/>

Contact: Jrgen Sperber
juergen.sperber@braunschweig.de
49-531-470-2212
Stadtverwaltung Braunschweig
8-Jul-2003


Page: 1 2

Related biology news :

1. Half-million dollar landmark achieved for the Methuselah Mouse Prize
2. Winner of 2004 EMBO Science Writing Prize announced
3. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
4. Stuart Lipton honored with Jung Prize for Medicine
5. 2004 Max Planck Research Prize for Martin Vingron and Eugene W. Myers
6. Scripps research scientist wins 2004 Koch Prize
7. Ohio State wetlands professor wins prestigious Water Prize
8. Tony Hunter and Raymond N. DuBois awarded Landon-AACR Prizes for Cancer Research
9. Leibniz Prizewinners 2004
10. Roderick MacKinnon wins 2003 Nobel Prize in Chemistry
11. Illinois professor wins Nobel Prize

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Braunschweig Prize for Molecular Cancer Therapy

(Date:2/5/2015)... New Market Research Reports Title ... To 2020 has Been Added to GrandViewReseach.com Report Database ... to reach USD 5.10 billion by 2020, according to ... cameras help identify the site of tissue damage in ... demand in medical imaging applications. They have been extensively ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ... A Global Market Overview" report to their offering. ... to ensure that an individual is who she/he is claiming ... use of a person,s unique physical characteristics, such as fingerprint, ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
(Date:2/26/2015)... Feb. 26, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... President and Chief Executive Officer of Regulus, will present ... th Annual Healthcare Conference on Wednesday, March 4, ... held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... 26, 2015 The Movement for Indefinite ... support life extension technologies and awareness. The event is ... Time, on March 21st 2015, in a live Google ... Eric Schulke, Founder of MILE, says, “Our lives are ... The Movement for Indefinite Life Extension is raising awareness ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015 The ... navigate this ever-changing arena, Frost & Sullivan will host its ... & Sullivan Executive MindXchange , March 8 to 10, at ... San Diego, Calif. This event is ... connected healthcare leaders to discuss industry disruptions and how to ...
(Date:2/26/2015)... February 26, 2015 Already well respected ... line by expanding its Length Gauge offerings with new ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length ... specification. Two new 1Vpp, 12mm stroke length variants ... applications. One is a variant with a weak spring, ...
Breaking Biology Technology:Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2
Cached News: